DrugDashboards

Fosaprepitant

Fosaprepitant Dimeglumine · FOSAPREPITANT DIMEGLUMINE 150 mg/5mL · Injection, Powder, Lyophilized, For Solution · Intravenous · Baxter Healthcare Corporation

NDC 00338-0008-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 5 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

11 companies supply this market — deep enough that no single failure threatens the supply.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$20.00$40.00Aug 2024Aug 2024$38.51
1 price point · per · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$30.00
Reported to Texas DSHS · 2025 annual filing · Baxter Healthcare Corporation

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2024)

$638
24 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $193.00 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA211860
TE code
—
Approval date
Sep 5, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Fosaprepitant Dimeglumine (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Avenacy, LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
BluePoint LaboratoriesFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Eugia US LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Merck Sharp & Dohme LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
NorthStar RxLLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCFOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Qilu Pharmaceutical Co., Ltd.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.FOSAPREPITANT DIMEGLUMINE 150 mg/5mLJul 15, 2026Sep 1, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Fosaprepitant — NDC 00338-0008-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00338000801.

Free to cite with attribution — see how the data is put together.